← Back to Search

Antioxidant

Antioxidants for ALS (MICABO-ALS Trial)

Phase 2
Waitlist Available
Led By Olaf Stuve, M.D., Ph.D.
Research Sponsored by Dallas VA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial is testing high amounts of anti-oxidants to help patients with ALS, a severe disease with no effective treatments. The goal is to see if these substances can protect nerve cells by stopping harmful molecules from causing damage. Edaravone, an antioxidant, has shown some efficacy in slowing ALS progression by reducing reactive oxygen species.

Eligible Conditions
  • Lou Gehrig's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Measurement of serum NfL
Secondary study objectives
Frequency of serious adverse events and adverse events.
Measurement of functional decline in ALS
Survival analysis
Other study objectives
Change in serum CK level from baseline to 12 months

Trial Design

1Treatment groups
Experimental Treatment
Group I: AntioxidantsExperimental Treatment1 Intervention
Eligible patients will receive over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Antioxidants
2005
Completed Phase 4
~7310

Find a Location

Who is running the clinical trial?

Dallas VA Medical CenterLead Sponsor
34 Previous Clinical Trials
4,776 Total Patients Enrolled
Olaf Stuve, M.D., Ph.D.Principal InvestigatorDallas VA Medical Center
1 Previous Clinical Trials
9 Total Patients Enrolled

Media Library

Antioxidants (Antioxidant) Clinical Trial Eligibility Overview. Trial Name: NCT04244630 — Phase 2
~18 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top